What is Spinal Muscular Atrophy?
Spinal Muscular Atrophy (SMA) is a rare, genetically inherited neuromuscular condition. It causes progressive muscle weakness and loss of movement due to muscle wasting (atrophy). This may affect crawling and walking ability, arm, hand, head and neck movement, breathing and swallowing. There are different forms of SMA and a wide spectrum of how severely children, young people and adults are affected.
The most common form of SMA is known as ‘5q SMA’ due to its genetic cause. 5q SMA includes the different "Types" or clinical classifications - Types 1, 2, 3 and 4.
There are also rarer forms of SMA that have different genetic (non-5q SMA) causes. Information about some of these can be found here.
This page tell you more about 5q SMA:
What are SMA Types 1, 2, 3 & 4?
What causes 5q SMA?
How is it inherited?
How many people are affected?
Is there a treatment or cure?
It’s important as you read this guide to remember that:
- Each child and adult is affected differently
- Although SMA is clinically classified into different ‘Types’ which reflect the severity of its impact, it is considered a spectrum
- For children and adults, the severity of the condition varies from person to person, both within and between ‘Types’
SMA Types 1, 2, 3 & 4
Symptoms of SMA Types 1, 2 and 3 begin at different ages in childhood. Symptoms of SMA Type 4 begin in adulthood. The types are defined by the best developmental milestone achieved, for example if a child is able to walk at some point then they have SMA Type 3.
Sometimes, as well as being diagnosed with a Type of SMA, a child may also be described as ‘strong’ or weak’ or having ‘early onset’ or ‘later onset’. This can be confusing as sometimes this refers to breathing being affected, yet at other times, it may mean age of onset. The International Standards of Care for SMA1,2 talk about classifications a, b and sometimes c – these describe the age of onset of the SMA.
A child / young person’s ability to sit, stand or walk and how their breathing ability is affected by their SMA are also important when it comes to managing the condition. Bearing all this in mind, broadly speaking, each type of SMA is currently understood to be as follows:
- SMA Type 1: is the most severe form of SMA with symptoms usually beginning between 0 and 6 months. Generally speaking, the earlier the onset of symptoms the more severe the condition. Babies are unable to sit without support and may be described as ‘non-sitters’. It‘s not possible to predict life expectancy accurately but for most children, without intervention for breathing difficulties, this has previously been estimated as less than two years3. Evidence suggests that since the International Standards of Care for SMA introduced more proactive managements in 2007, children have been living longer1.
You can read more about the symptoms, diagnosis and effects of SMA Type 1 here. If you are a parent or carer, you may find it helpful to read our guide: ‘Looking after your child who has had a recent diagnosis of SMA Type 1’.
- SMA Type 2: symptoms usually begin between the ages of 7 and 18 months. Children are unable to stand without support and may be described as ‘sitters’. Their weak respiratory muscles can make it difficult for them to cough effectively, which can make them more vulnerable to chest (respiratory) infections. Though this is a serious condition that may shorten life expectancy4, improvements in care standards mean that the majority of people can live long, fulfilling lives.
You can read more about the symptoms, diagnosis and effects of SMA Type 2 here. If you are a parent or carer, you may find it helpful to read our guide: ‘Looking after your child who has had a recent diagnosis of SMA Type 2'.
- SMA Type 3a: symptoms usually begin between 18 months and 3 years of age. Children can stand and walk, though this will become more difficult with age and they will need more support over time.
In SMA Type 3b, symptoms usually begin after 3 years. Difficulties with standing and walking usually occur later than they do for children with SMA Type 3a. Depending upon the individual impact of their condition, children and adults with SMA Type 3 may be described as ‘sitters’ or ‘walkers’. Very few people with SMA Type 3 have breathing problems and their life expectancy isn’t usually affected5. Most can live long, fulfilling lives.
You can read more about the symptoms, diagnosis and effects of SMA Type 3 here. If you are a parent or carer, you may find it helpful to read our guide: ‘Looking after your child who has had a recent diagnosis of SMA Type 3'.
- SMA Type 4: symptoms begin in adulthood and include mild to moderate muscle weakness in the arms and legs and some difficulty walking. SMA Type 4 isn’t life-threatening6.
You can read more about the symptoms, diagnosis and effects of SMA Type 4 here. Our guide, ‘Looking after yourself if you are an adult who has had a recent diagnosis of SMA’ answers many questions asked by adults newly diagnosed with SMA Type 4.
What causes 5q SMA?
- The SMN1 gene
All types of 5q SMA affect the nerve cells called lower motor neurons. These are found within the spinal cord and transmit signals to muscles. These nerve cells carry electrical signals from the brain to activate the muscles used for movement such as crawling and walking. These signals control movement of arms, hands, head and neck as well as breathing and swallowing. For these nerve cells to be healthy, our Survival Motor Neuron 1 genes (SMN1 genes7) must produce enough Survival Motor Neuron (SMN) protein.
The SMN1 gene is on the fifth chromosome in the region labelled ‘q’. This is why the main types of SMA are often referred to as 5q SMA.
Most people have two copies of the SMN1 gene. People with 5q SMA have two faulty copies of the SMN1 gene, which means they are unable to produce enough SMN protein to have healthy lower motor neurons6. This means these specialist nerve cells in the spinal cord deteriorate. This restricts the delivery of signals from the brain to their muscles, making movement difficult. The muscles then waste due to lack of use - this is known as muscular atrophy.
- The SMN2 gene7
A second gene also has a role in producing SMN protein. This is the Survival Motor Neuron 2 gene (SMN2), sometimes referred to as the SMA “back-up gene”.
However, most of the SMN protein produced by SMN2 lacks a key building block that is usually produced by SMN1. This means that while SMN2 can make some functional SMN protein, it cannot fully make up for the faulty SMN1 gene in people with SMA.
Unlike most genes, the number of copies of SMN2 on each chromosome can vary from one person to the next8; this can be between 0 – 8 copies. At the population level, the severity of SMA is linked to how much SMN protein is made1,8,9; there is therefore a general relationship between the number of SMN2 copies (“SMN2 copy number”) and the likely severity of SMA symptoms1,8,9. Having more SMN2 copies is generally associated with less severe SMA symptoms. However, at the individual level, accurate predictions cannot be made about the Type or severity of SMA based on the SMN2 copy number alone1. This is likely to be because other genetic and possibly environmental factors have an influence on the disease.
Bearing this in mind, the following table gives a summary of:
- how many SMN2 copies the majority of people within each type of SMA may have (see ‘usual’ column)1
- the possible range of copy numbers that people within each type of SMA may have (see ‘range’ column)10
|SMA Type||Usual age of symptoms10||SMN2 copies|
|Type 1||Younger than 6 months||2||1-3|
|Type 2||6-18 months||3||2-4|
|Type 3a||Under 3 years||3||3-5|
|Type 3b||Over 3 years||4|
|Type 4||Over 18 years||4-6|
Table adapted from Tillmann et al. 201810
How do people inherit 5q SMA?
5q SMA is passed from parents to their children through faulty SMN1 genes. It usually follows an autosomal recessive pattern of inheritance. This means that:
- People who have inherited two faulty copies of the SMN1 gene (one from each parent) have SMA.
- People who have inherited one faulty copy and one healthy copy of the SMN1 gene (one from each parent) are carriers of SMA. Carriers usually do not have SMA or any symptoms of SMA.
- People who have inherited two healthy copies of the SMN1 gene (one from each parent) do not have SMA and are not carriers.
When two SMA carriers have a child together for each pregnancy there is a:
- 1 in 4 (25%) chance that the child will inherit both faulty copies of the SMN1 gene and will have SMA.
- 1 in 2 (50%) chance that the child will inherit one faulty copy and one healthy copy of the SMN1 gene and will be a carrier.
- 1 in 4 (25%) chance that the child will inherit two healthy copies of the SMN1 gene and will not be a carrier or have SMA.
In around 2% of cases of SMA the mutation is new in the affected person most likely due to an error in making the egg or sperm cell from which they were conceived. This is called a de novo mutation.
There are other rarer forms of SMA with different genetic causes and different patterns of inheritance. For more information on these, please click here.
How many people are affected by SMA?
Approximately 1 in 40 people carry the faulty SMN1 gene11 - that means there are around 1.6 million carriers in the UK.
The incidence is the number of new cases of a condition or disease at any one time. Recent studies indicate that approximately one in every 10,000 babies worldwide are born with a Type of SMA, and that Type 1 SMA accounts for approximately 60% of cases11,12.
In the UK in 2017, there were 755,043 live births13-15. This suggests that in that year approximately 76 babies were born with a Type of 5q SMA.
The prevalence is how many people are living with a condition or disease in a population at any one time. Recent studies suggest between 1 and 2 people in every 100,000 worldwide have a Type of SMA11,12.
In 2017, the UK population was approximately 66 million16. Based on this, it is estimated that between 660 and 1320 people have SMA in the UK at any one time. Previous estimates by clinicians have suggested an upper limit likely to be 2,500. As there is no central information source the exact numbers are unknown.
Is there a treatment or cure for 5q SMA?
Although there is currently no cure for SMA, this does not mean that nothing can be done. There are a range of options aimed at managing symptoms, reducing complications of muscle weakness and maintaining the best quality of life. These are outlined in the internationally agreed Standards of Care for SMA 1,2.
Nusinersen / SpinrazaTM
The first (and currently, the only) potentially available drug treatment for SMA is called nusinersen. Essentially the drug is designed to modify the SMN protein produced by the SMN2 gene so that more of it is functional.
In collaboration with researchers, nusinersen was developed by Ionis Pharmaceuticals and Biogen Idec which have run clinical trials with infants and children affected by SMA Types 1, 2 or 3. There have not yet been any clinical trials of nusinersen with anyone with SMA Type 4. On June 1st 2017, the European Commission (EC) approved nusinersen for marketing under its brand name SpinrazaTM as a treatment for those with 5q SMA17. Following any EC marketing approval it’s up to each country to decide who can be prescribed the drug.
Currently in the UK, nusinersen is only available in Scotland if the medical team and family agree that an infant with SMA Type 1 is eligible and may potentially benefit from the treatment.
To find out more about how nusinersen works, the clinical trial results and what stage access has reached in the UK, please explore this section of our website.
Research and further developments
There is a considerable amount of research into SMA taking place around the world. This research will not only improve our understanding of the condition, but will also help to develop effective treatments.
One area of extensive research is the genetics of SMA and the underlying mechanisms that lead to damage of the nerve cells. The UK is a significant contributor to this, with several UK centres involved in clinical trials and international collaborations. This has led to encouraging breakthroughs in developing treatments.
For the latest developments with drug treatments, the science behind them, and what clinical trials and other research is going on, please click here.
Resources and support
The International Standards of Care for Spinal Muscular Atrophy (2017) can be read / downloaded from here.
SMA Support UK
We provide free information and support to families in the UK affected by SMA. Our outreach workers are able to visit you at home. They offer personalised support and information and are available to answer questions. They can discuss with you the support you and your family can access. Please note, we do not give medical advice.
Our monthly E-news will keep you informed about developments in services and research, campaigns and surveys, social and fundraising events and other general information and news. Each time we send this, you have the option to unsubscribe. You can opt in to receive this here.
Our Route Maps for SMA have other information about day-to-day life with SMA and signpost to possible sources of support and advice. At the moment they are organised according to type of SMA. You can find these here.
We are currently re-organising this information so that it’s more accessible. It will be located on a new part of our website which we will call ‘Living with SMA’. As soon as it’s ready we’ll let people know via our monthly e-news.
Muscular Dystrophy UK
Phone: 0800 652 6352
MDUK provide information, support, advocacy services and grants towards specialist equipment for people affected by a range of neuromuscular conditions.
Author: SMA Support UK Information Production Team
First published: September 2018
Next full review due September 2021
- Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Qian Y, Sejersen T; SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb;28(2):103-115. doi:10.1016/j.nmd.2017.11.005. Epub 2017 Nov 23. http://smasupportuk.org.uk/international-standards-of-care-for-sma (Accessed 29 August 2019)
- Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y,Sejersen T; SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar;28(3):197-207. doi: 10.1016/j.nmd.2017.11.004. Epub 2017 Nov 23. http://smasupportuk.org.uk/international-standards-of-care-for-sma (Accessed 29 August 2019)
- Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A; Participants of the International Conference on SMA Standard of Care (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22: 1027-1049. Available at: www.treat-nmd.eu/care/sma/care-standards/ (Accessed: 29 August 2018)
- Farrar MA, Vucic S, Johnston HM, duSart D, Kiernan MC (2013) Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatrics 162: 155-159.
- Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I (1997) A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 146: 67-72.
- Lunn MR, Wang CH (2008) ‘Spinal muscular atrophy’, Lancet, 371: 2120-2133.
- Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Frézal J, Cohen D, Weissenbach J, Munnich A, Melki J (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165.
- Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AHM, Prior TW (2002). Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4: 20–26.
- Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265–269.
- R.Tillmann, M. Main, L.Abbot, L. Edel, M. Scoto, F. Muntoni (2018), Spinal Muscular Atrophy (SMA) type 1, a changing phenotype: implications for motor function and physiotherapy management from the Nusinersen Expanded Access Program (EAP)’ APCP Journal Volume 9 Number 1 (2018)
- Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, Cook SF, Lochmüller H (2017) Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy –a literature review. Orphanet J Rare Dis 12: 124.
- Verhaart IEC, Robertson A, Leary R, McMacken G, König K, Kirschner J, Jones CC, Cook SF, Lochmüller H. (2017) A multi-source approach to determine SMA incidence and research ready population. J Neruol 264: 1465-1473.
- Office of National Statistics (2018) ‘Births in England and Wales: 2017’. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/births
englandandwales/2017 (Accessed:26 August 2018)
- National Records of Scotland (2018) Available at: https://www.nrscotland.gov.uk/news/2018/5000-more-deaths-than-births-in-2017 (Accessed: 26 August 2018)
- Northern Ireland Statistics and Research Agency (2018) ‘Monthly Births’’. Available at: https://www.nisra.gov.uk/publications/monthly-births (Accessed:26 August 2018)
- Office for National Statistics ‘Overview of the UK Population: July 2018.’ Available at: www.ons.gov.uk/peoplepopulationandcommunity/population
populationestimates/mid2017#main-points (accessed 26 August 2018)
- European Medicines Agency (2017) ‘Committee for Medicinal Products for Human Use Assessment Report Spinraza’ (EMA/289068/2017). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004312/WC500229706.pdf (Accessed: 29 August 2018)
We are grateful to the writers and reviewers who assist us in our information production. A list of who this includes may be viewed on our website: www.smasupportuk.org.uk/our-writers-and-reviewers-panel or requested from email@example.com
Whilst every effort is made to ensure that the information in this publication is complete, correct and up to date, this cannot be guaranteed. The collaborating organisations shall not be liable whatsoever for any damages incurred as a result of its use.
If you have any feedback about this information, please do let us know: firstname.lastname@example.org